Certara, Inc. (CERT) Stock Analysis and Metrics

Certara

NASDAQ: CERT

$7.49 ▲ +0.38 (+5.41%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.12 Bn

P/E-74.28

P/S2.67

Div. Yield0.00

ROIC (Qtr)0.02

Total Debt (Qtr)292.47 Mn

Revenue Growth (1y) (Qtr)0.86

Add ratio to table…

About

Certara, Inc. is a global leader in biosimulation science technology and consulting services for Model Informed Drug Development serving the biopharmaceutical and biotech industry. The company helps clients use data modeling and analytics to make better decisions during drug research development and commercialization. Its offerings include mechanistic and empirical simulation platforms data management tools and regulatory support services that are used throughout the drug lifecycle.

Certara generates revenue primarily from licensing its proprietary software platforms and from providing technology enabled services and consulting projects. Software sales come from products such as the Simcyp simulator for mechanistic pharmacokinetic analysis the Phoenix PK/PD suite for pharmacokinetic and pharmacodynamic data and the Pinnacle 21 family for clinical data standardization and validation. Service revenue is earned when scientists work with clients to design simulations interpret results prepare regulatory submissions and provide expertise in areas such as quantitative systems pharmacology and regulatory strategy. The company earns fees from its AI enabled offerings such as Certara. AI and the CoAuthor writing tool which help automate document creation and data analysis.

The company operates through the following segments.

• Biosimulation Solutions: This segment provides mechanistic and empirical simulation tools such as the Simcyp simulator for predicting drug absorption distribution and the Phoenix PK/PD suite for analyzing pharmacokinetic and pharmacodynamic data to support dose selection trial design drug interaction studies and includes specialized add ons for biopharmaceutics secondary information and pediatric modeling that extend the platform’s utility across all stages of development.

• Scientific Informatics Solutions: This segment offers chemical property prediction and compound management software obtained through the acquisition of Chemaxon including tools for chemical search registration design and visualization that aid early stage drug discovery and provides workflow integration with the Certara D360 platform to streamline lead optimization and structure activity relationship analysis for biologic candidates.

• Preclinical & Clinical Data Pipeline Solutions: This segment supplies data standardization and validation products like the Pinnacle 21 platform and associated metadata repository and data exchange tools that enable clients to prepare clean analysis ready datasets for regulatory submission and also offers automation solutions for converting study data into the standardized tabular format required by regulators and for managing protocol definitions and metadata across global clinical trials.

• Regulatory Science Solutions: This segment delivers expertise and software for creating and managing regulatory documents including the CoAuthor authoring tool with generative AI and the GlobalSubmit platform for electronic common technical document preparation and submission and also provides regulatory writing consulting and project management services that help clients navigate complex submission requirements for the FDA EMA PMDA and other health authorities.

• Technology Enabled Services: This segment provides consulting and implementation services where Certara scientists apply biosimulation and data analytics to client projects offering support in quantitative systems pharmacology clinical pharmacology drug development strategy and regulatory operations and the team also conducts quantitative systems pharmacology modeling for immunogenicity immuno oncology and neurodegenerative disease programs and assists with the preparation of commercialization plans and post launch evidence generation.

Certara holds a strong position in the biosimulation market where it competes with established technology firms such as Mathworks Dassault Systemes Ansys Simulations Plus and the NONMEM division of ICON as well as with open source tools like R and PK Sim. The company differentiates itself through its scientific expertise proprietary models validated over two decades and its integration of artificial intelligence within expert reviewed workflows that meet regulatory expectations for transparency and reproducibility. Its long standing relationships with major drug regulators including the FDA EMA PMDA and NMPA and its extensive patent portfolio further reinforce its competitive barrier to entry.

Certara serves a diverse customer base that includes more than 2600 biopharmaceutical and biotech companies academic institutions contract research organizations and government agencies across seventy countries. Its software is licensed by over 160000 users and by twenty global drug regulators such as the US Food and Drug Administration the European Medicines Agency Japans Pharmaceuticals and Medical Devices Agency Chinas Center for Drug Evaluation and the UK Medicines and Healthcare Products Regulatory Agency. The company notes that no single customer accounts for more than ten percent of its revenue and its ten largest customers together contributed roughly a quarter of sales in recent years.

Investment Thesis

▲ Bull case

Certara's strategic reorganization into MID3 (Model-Informed Drug Development and Discovery) and ACE (Accelerated Clinical Evidence) segments represents a fundamental shift to enhance predictability and synergy between its software and services businesses, addressing a key pain point of inconsistent quarterly performance. By integrating technology and expert services within MID3, the company creates a self-reinforcing flywheel where software innovation drives service demand and service insights refine product development, a dynamic management emphasized as critical to long-term stability. This structural change, coupled with the divestiture of the lower-margin, lumpier medical writing business, sharpens focus on high-value, sticky offerings where Certara possesses deep regulatory trust and scientific moats—such as Simcyp’s EMA qualification for drug-drug interaction prediction, a process requiring two years of pan-European engagement and 25 years of data validation that competitors cannot replicate quickly. The resulting revenue mix targeting 50% software and 50% services is expected to improve forecastability and unlock approximately 150 basis points of incremental growth from 2027 onward, as the company sheds non-core volatility while doubling down on its core competency in model-informed frameworks now bolstered by global regulatory tailwinds like ICH M15 and FDA NAMs guidance.
The company’s nascent AI-integrated platform, though not yet monetized, leverages Certara’s unparalleled clinical intelligence asset base—over 10,000 projects, 160,000 users, 36 trillion validated data points in Pinnacle 21, and deep regulatory relationships—to transform decades of tacit knowledge into systematic, auditable AI-driven insights. Unlike generic AI entrants, Certara’s approach embeds proprietary science, validated biological parameters, and regulatory workflow expertise directly into its technology, addressing the “last mile” of regulatory science where transparency and traceability are non-negotiable. Management’s deliberate pacing—engaging lighthouse customers, avoiding premature disclosures, and tying investments to clear business cases—reflects disciplined capital allocation, with returns expected to materialize in 2027 and beyond as the platform scales. The NVIDIA collaboration, focused on accelerating computationally intensive simulations like PBPK and QSP through parallel processing, directly tackles a bottleneck in early discovery, potentially democratizing access to complex modeling across broader R&D teams and expanding addressable markets beyond Tier 1 pharma to include agile biotechs seeking resource-efficient proof-of-concept pathways.
Certara’s positioning at the intersection of AI-driven drug discovery and regulatory acceleration creates a powerful compounding tailwind: as AI generates more drug candidates (evidenced by over 200 AI-designed molecules in clinical development), demand for Certara’s MIDD capabilities to de-risk and accelerate development intensifies, while FDA real-time trial initiatives and ICH M15 guidance increase the value of model-informed approaches that reduce reliance on traditional clinical endpoints. The company’s recent success in using PBPK modeling to replace clinical bioequivalence studies for a generic tazarotene approval—and its role in asciminib’s leukemia therapy approval, where Simcyp data substituted for at least 10 human trials—demonstrates tangible, recurring value in cutting development time and cost. These validated use cases, reinforced by nearly 100 peer-reviewed publications this year aligning with ICH M15, signal that Certara is not merely benefiting from industry trends but actively shaping regulatory acceptance of its methodologies, creating a self-reinforcing cycle where scientific leadership drives adoption, which in turn fuels further innovation and regulatory trust.

Certara's strategic reorganization into MID3 (Model-Informed Drug Development and Discovery) and ACE (Accelerated Clinical Evidence) segments represents a fundamental shift to enhance predictability and synergy between its software and services businesses, addressing a key pain point of inconsistent quarterly performance. By integrating technology and expert services within MID3, the company creates a self-reinforcing flywheel where software innovation drives service demand and service insights refine product development, a dynamic management emphasized as critical to long-term stability. This structural change, coupled with the divestiture of the lower-margin, lumpier medical writing business, sharpens focus on high-value, sticky offerings where Certara possesses deep regulatory trust and scientific moats—such as Simcyp’s EMA qualification for drug-drug interaction prediction, a process requiring two years of pan-European engagement and 25 years of data validation that competitors cannot replicate quickly. The resulting revenue mix targeting 50% software and 50% services is expected to improve forecastability and unlock approximately 150 basis points of incremental growth from 2027 onward, as the company sheds non-core volatility while doubling down on its core competency in model-informed frameworks now bolstered by global regulatory tailwinds like ICH M15 and FDA NAMs guidance.
The company’s nascent AI-integrated platform, though not yet monetized, leverages Certara’s unparalleled clinical intelligence asset base—over 10,000 projects, 160,000 users, 36 trillion validated data points in Pinnacle 21, and deep regulatory relationships—to transform decades of tacit knowledge into systematic, auditable AI-driven insights. Unlike generic AI entrants, Certara’s approach embeds proprietary science, validated biological parameters, and regulatory workflow expertise directly into its technology, addressing the “last mile” of regulatory science where transparency and traceability are non-negotiable. Management’s deliberate pacing—engaging lighthouse customers, avoiding premature disclosures, and tying investments to clear business cases—reflects disciplined capital allocation, with returns expected to materialize in 2027 and beyond as the platform scales. The NVIDIA collaboration, focused on accelerating computationally intensive simulations like PBPK and QSP through parallel processing, directly tackles a bottleneck in early discovery, potentially democratizing access to complex modeling across broader R&D teams and expanding addressable markets beyond Tier 1 pharma to include agile biotechs seeking resource-efficient proof-of-concept pathways.
Certara’s positioning at the intersection of AI-driven drug discovery and regulatory acceleration creates a powerful compounding tailwind: as AI generates more drug candidates (evidenced by over 200 AI-designed molecules in clinical development), demand for Certara’s MIDD capabilities to de-risk and accelerate development intensifies, while FDA real-time trial initiatives and ICH M15 guidance increase the value of model-informed approaches that reduce reliance on traditional clinical endpoints. The company’s recent success in using PBPK modeling to replace clinical bioequivalence studies for a generic tazarotene approval—and its role in asciminib’s leukemia therapy approval, where Simcyp data substituted for at least 10 human trials—demonstrates tangible, recurring value in cutting development time and cost. These validated use cases, reinforced by nearly 100 peer-reviewed publications this year aligning with ICH M15, signal that Certara is not merely benefiting from industry trends but actively shaping regulatory acceptance of its methodologies, creating a self-reinforcing cycle where scientific leadership drives adoption, which in turn fuels further innovation and regulatory trust.

▼ Bear case

Despite Certara’s optimistic framing of its AI platform and strategic reorganizations, the company faces significant execution risk in transitioning from legacy product silos to a unified, monetizable AI ecosystem, with near-term revenue contribution likely minimal and uncertain. Management repeatedly deferred concrete guidance on the platform’s monetization, emphasizing lighthouse customer engagement and 2027+ impact, while acknowledging the initiative remains in “active discussion” without disclosing pricing models, adoption pathways, or clear ASP uplift potential. This vagueness, coupled with historical inconsistencies in translating R&D spend into durable growth—evidenced by fluctuating services performance and mixed tier-specific results despite software bookings strength—suggests the market may be overestimating the speed and scale of AI-driven transformation. The divestiture of the medical writing business, while presented as a focus-enhancing move, removes a stable $50 million annual revenue stream and ~$17 million of adjusted EBITDA, creating a near-term gap that must be filled by unproven initiatives; the promised 150 basis points of incremental growth from 2027 relies on assumptions about successful reallocation and execution discipline that have not yet been consistently demonstrated, particularly given the company’s history of operational churn during transitions.
Certara’s reliance on deep regulatory trust and proprietary data as a moat is increasingly challenged by the evolving landscape of AI in drug development, where large pharmaceutical companies and tech giants are aggressively building internal capabilities that could erode demand for third-party MIDD services. While management argued that replicating Certara’s legacy—such as the EMA-qualified Simcyp model requiring two years of multi-stakeholder engagement—is “hugely inefficient,” this underestimates the resources and strategic focus of well-capitalized players like Eli Lilly (partnered with NVIDIA on a dedicated AI lab) and Roche/Genentech (launching a hybrid cloud AI factory), who are investing heavily in internal AI and simulation infrastructure. The growing trend of pharma building in-house solutions, particularly in discovery and biologics-adjacent areas like QSP, poses a structural threat: if sponsors develop trusted, integrated internal tools that meet regulatory needs, Certara’s value proposition as an external expert-services provider could diminish, especially as AI lowers barriers to creating auditable, transparent models. The company’s acknowledgment of “phone calls” from large pharma seeking to tap its capabilities suggests a partnership-dependent future rather than enduring dominance, exposing it to shifting client strategies and potential disintermediation.
Near-term financial performance remains vulnerable to execution gaps in the services segment, where softness in Tier 1 MIDD demand and persistent lumpiness could undermine guidance-dependent recovery in the second half of 2026, despite optimistic backlog conversion assumptions. Services revenue declined 4% year-over-year in Q1, with bookings down 14%, reflecting ongoing weakness in regulatory services and uneven customer tier performance—strong in Tiers 2 and 3 but lacking clear Tier 1 momentum beyond Simcyp. While management attributes this to execution dynamics and expects improvement via backlog and sales realignment, the reliance on backlog conversion introduces timing risk; if drug developers delay projects due to macroeconomic uncertainty or shifting R&D priorities, the anticipated second-half ramp may not materialize, leaving adjusted EPS guidance of $0.35–$0.41 dependent on optimistic software growth and margin expansion. Furthermore, the $7.4 million increase in operating expenses from the Vyasa acquisition’s contingent consideration fair value change—highlighted as a primary driver of higher total operating expenses—underscores lingering integration risks from past M&A, suggesting that even as Certara pursues tuck-in opportunities, legacy liabilities could continue to distort profitability and distract from core growth initiatives, particularly if AI investments fail to deliver timely returns amid rising R&D spend.

Despite Certara’s optimistic framing of its AI platform and strategic reorganizations, the company faces significant execution risk in transitioning from legacy product silos to a unified, monetizable AI ecosystem, with near-term revenue contribution likely minimal and uncertain. Management repeatedly deferred concrete guidance on the platform’s monetization, emphasizing lighthouse customer engagement and 2027+ impact, while acknowledging the initiative remains in “active discussion” without disclosing pricing models, adoption pathways, or clear ASP uplift potential. This vagueness, coupled with historical inconsistencies in translating R&D spend into durable growth—evidenced by fluctuating services performance and mixed tier-specific results despite software bookings strength—suggests the market may be overestimating the speed and scale of AI-driven transformation. The divestiture of the medical writing business, while presented as a focus-enhancing move, removes a stable $50 million annual revenue stream and ~$17 million of adjusted EBITDA, creating a near-term gap that must be filled by unproven initiatives; the promised 150 basis points of incremental growth from 2027 relies on assumptions about successful reallocation and execution discipline that have not yet been consistently demonstrated, particularly given the company’s history of operational churn during transitions.
Certara’s reliance on deep regulatory trust and proprietary data as a moat is increasingly challenged by the evolving landscape of AI in drug development, where large pharmaceutical companies and tech giants are aggressively building internal capabilities that could erode demand for third-party MIDD services. While management argued that replicating Certara’s legacy—such as the EMA-qualified Simcyp model requiring two years of multi-stakeholder engagement—is “hugely inefficient,” this underestimates the resources and strategic focus of well-capitalized players like Eli Lilly (partnered with NVIDIA on a dedicated AI lab) and Roche/Genentech (launching a hybrid cloud AI factory), who are investing heavily in internal AI and simulation infrastructure. The growing trend of pharma building in-house solutions, particularly in discovery and biologics-adjacent areas like QSP, poses a structural threat: if sponsors develop trusted, integrated internal tools that meet regulatory needs, Certara’s value proposition as an external expert-services provider could diminish, especially as AI lowers barriers to creating auditable, transparent models. The company’s acknowledgment of “phone calls” from large pharma seeking to tap its capabilities suggests a partnership-dependent future rather than enduring dominance, exposing it to shifting client strategies and potential disintermediation.
Near-term financial performance remains vulnerable to execution gaps in the services segment, where softness in Tier 1 MIDD demand and persistent lumpiness could undermine guidance-dependent recovery in the second half of 2026, despite optimistic backlog conversion assumptions. Services revenue declined 4% year-over-year in Q1, with bookings down 14%, reflecting ongoing weakness in regulatory services and uneven customer tier performance—strong in Tiers 2 and 3 but lacking clear Tier 1 momentum beyond Simcyp. While management attributes this to execution dynamics and expects improvement via backlog and sales realignment, the reliance on backlog conversion introduces timing risk; if drug developers delay projects due to macroeconomic uncertainty or shifting R&D priorities, the anticipated second-half ramp may not materialize, leaving adjusted EPS guidance of $0.35–$0.41 dependent on optimistic software growth and margin expansion. Furthermore, the $7.4 million increase in operating expenses from the Vyasa acquisition’s contingent consideration fair value change—highlighted as a primary driver of higher total operating expenses—underscores lingering integration risks from past M&A, suggesting that even as Certara pursues tuck-in opportunities, legacy liabilities could continue to distort profitability and distract from core growth initiatives, particularly if AI investments fail to deliver timely returns amid rising R&D spend.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Health Information Services

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VEEV	Veeva Systems Inc	29.34 Bn	31.16	8.84	-
2	BTSG	BrightSpring Health Services, Inc.	13.49 Bn	46.18	0.99	2.50 Bn
3	HQY	Healthequity, Inc.	7.96 Bn	34.51	5.95	0.94 Bn
4	TXG	10x Genomics, Inc.	6.17 Bn	-272.14	9.65	-
5	HNGE	Hinge Health, Inc.	6.02 Bn	-11.77	9.31	-
6	MMED	MiniMed Group, Inc.	4.19 Bn	-8.88	1.38	-
7	WAY	Waystar Holding Corp.	4.14 Bn	32.80	3.58	1.47 Bn
8	DOCS	Doximity, Inc.	3.82 Bn	19.51	5.93	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password